本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公司双鹤天安药业(贵州)股份有限公司(以下 简称"双鹤天安")收到贵州省药品监督管理局颁发的《药品GMP符合性检查告知书》(编号：黔 20250059)，现将相关情况公告如下： 一、GMP检查相关信息 被检查单位名称：双鹤天安药业(贵州)股份有限公司 检查地址：贵州省贵阳市乌当区高新路25号 检查范围及相关车间、生产线： 片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍500mg与恩格列净5mg)，综合车间(四)片剂生产线， 自行生产] 检查时间：2025年10月15日至10月17日 结论：符合 本次检查是二甲双胍恩格列净片(Ⅰ)上市前的首次药品GMP符合性检查。上述检查项目是在原有厂房、 设备情况下的检查，未投入资金。 二、本次检查所涉生产线及产品情况 生产车间生产线：综合车间(四)片剂生产线 生产线设计产能：5亿片/年 三、同类产品的市场状况 二甲双胍恩格列净片(Ⅰ)配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲 ...

Group 1: Company Performance - SMIC reported a revenue of 17.162 billion yuan in Q3 2025, a year-on-year increase of 9.9%, with a net profit of 1.51 billion yuan, up 43.1% year-on-year. For the first three quarters, revenue reached 49.51 billion yuan, growing 18.2%, and net profit was 3.81 billion yuan, an increase of 41.1% year-on-year [1] - BoRui Pharma's BGM1812 injection has received clinical trial approval for weight loss indications, with no similar targeted formulations approved globally [2] - Li Zhong Group's subsidiaries received project confirmations for aluminum alloy wheels from major international automotive manufacturers, with expected total sales of approximately 1.135 billion yuan [4] Group 2: Corporate Actions - Kanda New Materials announced the termination of the acquisition of equity in North One Semiconductor due to unmet progress expectations and lack of consensus among parties [3] - Lide Man plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the bioproducts industry [9] - Arctech's controlling shareholder CSIQ expects total revenue of 1.3 to 1.5 billion USD in Q4 2025, with a gross margin of 14% to 16% [6] Group 3: Market Activity - Taihe Technology's VC project phase two construction will be adjusted based on phase one market expansion, indicating some uncertainty [5] - Hezhong China has experienced significant stock price fluctuations, with a cumulative increase of 230.84% over 12 out of 13 trading days, leading to potential application for trading suspension if abnormal price increases continue [7][8]

证券日报网讯11月13日晚间，华润双鹤（600062）发布公告称，近日，华润双鹤药业股份有限公司(以 下简称"公司")控股子公司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到贵州省药品监督 管理局颁发的《药品GMP符合性检查告知书》。 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

华润双鹤药业股份有限公司 关于控股子公司双鹤天安药业(贵州)股份有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公 司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到贵 州省药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号： 黔 20250059)，现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：双鹤天安药业(贵州)股份有限公司 检查地址：贵州省贵阳市乌当区高新路 25 号 检查范围及相关车间、生产线： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－096 片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍 500mg 与恩 格列净 5mg)，综合车间(四)片剂生产线，自行生产] 检查时间：2025 年 10 月 15 日至 10 月 17 日 结论：符合 本次检查是二甲双胍恩格列净片(Ⅰ)上市前的首次药品 GMP 符合 性检查。上述检查项目是在原有厂房、设备情况下的检 ...

智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司双鹤天安药业(贵州)股份有限 公司(简称"双鹤天安")收到贵州省药品监督管理局颁发的《药品GMP符合性检查告知书》(编号：黔 20250059)。 本次检查范围及相关车间、生产线：片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍500mg与恩格 列净5mg)，综合车间(四)片剂生产线，自行生产]。生产线设计产能：5亿片/年。 ...

本次检查范围及相关车间、生产线：片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍500mg与恩格 列净5mg)，综合车间(四)片剂生产线，自行生产]。生产线设计产能：5亿片/年。 华润双鹤（600062）(600062.SH)发布公告，近日，公司控股子公司双鹤天安药业(贵州)股份有限公司 (简称"双鹤天安")收到贵州省药品监督管理局颁发的《药品GMP符合性检查告知书》(编号：黔 20250059)。 ...

华润双鹤公告，控股子公司双鹤天安药业(贵州)股份有限公司收到贵州省药品监督管理局颁发的《药品 GMP符合性检查告知书》。检查范围为片剂，检查时间为2025年10月15日至10月17日，结论为符合。 ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]